Professional Diversity, Klotho Neurosciences, and Vor Biopharma are the 3 Penny Stocks to watch on July 1, 2025, based on TipRanks’ Penny Stock Screener tool. Penny stocks are defined as stocks that trade at or below $5 per share and have a market capitalization of below $300 million.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The Penny Stock Screener helps investors scan stocks based on numerous parameters, including Sector, Price Target Upside, Smart Score, Analyst Consensus, Dollar Volume, and Price Change.
We leveraged the tool to pick the top three penny stocks with the highest Dollar Volume as of the close on June 30, 2025. Simply put, Dollar Volume is the number of shares traded on a particular day multiplied by the day’s share price.
Professional Diversity (IPDN) – Professional Diversity Network develops and operates both online and in-person networks for diverse professionals, providing access to networking, training, educational, and employment opportunities.
On June 30, IPDN had a Dollar Volume of $186.57 million, while its stock price skyrocketed by more than 93%. There was no specific news about IPDN stock that could justify yesterday’s surge.
Klotho Neurosciences (KLTO) – Klotho Neurosciences is a biopharmaceutical company focused on developing disease-modifying therapies for age-related cognitive and neurodegenerative disorders. On Monday, KLTO had a Dollar Volume of $153.98 million, while its stock price surged by nearly 57%.
The company announced that it is moving ahead with the clinical trials of KLTO-202, its investigational gene therapy for amyotrophic lateral sclerosis (ALS). Klotho will begin manufacturing and process development work related to the trials, which is expected to take eight months to complete. The company expects to start the single-dose gene therapy studies in ALS patients by the third quarter of 2026. KLTO shares jumped in reaction to the news.
Vor Biopharma (VOR) – Vor Biopharma is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases. Yesterday, VOR had a Dollar Volume of $108.55 million, accompanied by a stock price surge of 52.8%.
VOR stock has been consistently rising over the past couple of trading days. On June 25, the company announced that it had entered into an exclusive global license agreement with RemeGen Co. (HK:9995), granting Vor global rights (excluding China, Hong Kong, Macau, and Taiwan) to develop and commercialize telitacicept. This drug is a novel dual-target fusion protein approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). As per the deal, Vor will pay RemeGen an upfront payment of $125 million.
Additionally, the company announced that it has entered into a securities purchase agreement for a private placement in public equity financing, which is expected to result in gross proceeds of approximately $175 million.
To find more penny stocks like these, you can take a look at TipRanks’ Penny Stock Screener tool. It shows a list of all penny stocks, their price movement, and other vital data.